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Abstract: Caveolins are a family of membrane proteins required for the formation of small plasma membrane 
invaginations called caveolae that are implicated in cellular trafficking processes. In addition to this structural 
role, these scaffolding proteins modulate numerous intracellular signaling pathways; often via direct interaction 
with specific binding partners. Caveolin-1 is particularly well-studied in this respect and has been attributed a 
large variety of functions. Thus, Caveolin-1 also represents the best-characterized isoform of this family with 
respect to its participation in cancer. Rather strikingly, available evidence indicates that Caveolin-1 belongs to 
a select group of proteins that function, depending on the cellular settings, both as tumor suppressor and 
promoter of cellular traits commonly associated with enhanced malignant behavior, such as metastasis and 
multi-drug resistance. The mechanisms underlying such ambiguity in Caveolin-1 function constitute an area of 
great interest. Here, we will focus on discussing how Caveolin-1 modulates cell death and survival pathways 
and how this may contribute to a better understanding of the ambiguous role this protein plays in cancer. 
Keywords: Caveolin-1, cell death, metastasis, multi-drug resistance, proliferation, tumor suppression. 
INTRODUCTION 
Caveolins 
 Caveolins are 21-24 kDa membrane-associated 
proteins that are highly enriched in specialized, 50-100 
nm omega-shaped invaginations of the plasma 
membrane referred to as caveolae [1]. Importantly, 
however, caveolae morphology can vary considerably 
from being flattened out within the plasma membrane, 
to individual invaginations of the membrane, multi-
vesicular rosette-like structures or even tubule-like 
structures (see below). This family of proteins includes 
the three principle members, Caveolin-1, Caveolin-2 
and Caveolin-3. Caveolin-1 and Caveolin-2 are present 
in many cell types and often co-expressed, while Cave-
olin-3 distribution is far more restricted and essentially 
limited to muscle and glia cells [2]. Caveolin-1 and -3 
form homo-oligomers, and oligomerization is essential 
for caveolae biogenesis. Double knock-out mice for 
Caveolins-1 and -3 completely lack caveolae. Cave-
olin-2 forms hetero-oligomers with Caveolin-1 and 
requires Caveolin-1 presence for stability. Thus, 
Caveolin-1 knock-out mice also lack Caveolin-2 [3-5]. 
While Caveolins are essential, they are not necessarily 
sufficient for caveolae formation. In the absence of 
proteins called cavins, the formation of morphologically 
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detectable caveolae or tubule structures is impaired [6-
9]. In the absence of cavins, Caveolins associate with 
microdomains of the plasma membrane and persist 
there as planar caveolae [10]. 
 Caveolins have been attributed multiple roles in 
cells besides caveolae formation, including vesicle 
trafficking, endocytosis, cholesterol homeostasis, as 
well as regulation of signal transduction, gene 
expression and protein turnover [10-11]. Since much of 
the information available with respect to these 
additional roles stems from studies dealing with the 
isoform Caveolin-1, we will center the rest of our 
discussion here on this isoform. 
Caveolin-1 
 The Caveolin-1 sequence harbors a central 
hydrophobic domain (residues 102-134), which is 
thought to adopt a hairpin-like conformation that inserts 
into the inner leaflet of the plasma membrane. 
Consequently, both carboxy- and amino-termini face 
the cytoplasm. A modular sequence, referred to as the 
“Caveolin Scaffolding Domain” (CSD; residues 82–101) 
is located adjacent to the hydrophobic domain, in the 
amino-terminal region, and is required for homo- and 
hetero-oligomerization, as well as for interaction with a 
plethora of signaling proteins [3]. In the carboxy-
terminal region, Caveolin-1 contains three palmitoy-
lated cysteine residues that are important for oligomeri-
zation, but not localization to caveolae [12-13], as well 
as a putative WW-like domain (residues 98-132), in 
analogy to that described for Caveolin-3 [14-15]. 
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 Two variants of Caveolin-1 referred to as 1 
(residues 1-174) and 1 (residues 34-174) can be 
distinguished, which are generated either from 
alternative transcripts or by alternative initiation from 
the same transcript [3, 16]. Both proteins are ascribed 
different roles in cells. Most notably, Caveolin-1 
contains a tyrosine residue in position 14 that is 
phosphorylated in response to a large number of 
different stimuli. Often, but not always, non-receptor 
tyrosine kinases of the Src family are involved and 
phosphorylation is triggered as part of a so-called 
stress response [11]. The importance of Caveolin-1 in 
this context is underscored by the fact that Caveolin-1 
knock-out mice display a remarkably reduced ability to 
regenerate specific tissues like the liver and also a 
dramatic decrease in life span [17-18]. Rather 
intriguingly, phosphorylation of Caveolin-1 is also 
considered highly relevant to cell migration and 
metastasis (see discussion later on). These examples 
suggest that Caveolin-1 is also important player in the 
regulation of signaling in cells. 
 Indeed, a large number of signaling pathways have 
been shown to be regulated by Caveolin-1 and such 
versatility highlights the importance of this protein and 
the potential for involvement in many pathologies, 
including cancer, where Caveolin-1 plays a highly 
ambiguous role that depends on a variety of factors as 
will be discussed [19]. An additional complexity is that, 
Caveolin-1 is found at the plasma membrane and also 
in other sub-cellular compartments, such as 
endoplasmic reticulum (ER), Golgi, endosomes, 
mitochondria and associated with the nucleus [20-22]. 
Thus, much of the existing confusion related to 
Caveolin-1 function that will be discussed, likely reflects 
the fact that it is often unclear which pool of Caveolin-1 
is implicated in a specific event. 
 Initially, Caveolin-1 was proposed to behave as a 
tumor suppressor, since presence of the protein was 
associated with inhibition of signaling pathways that 
favored cell proliferation and viability, while promoting 
basal or stimuli-induced cell death. Moreover, 
Caveolin-1 expression was shown to revert 
characteristics associated with cell transformation and 
inhibit tumor growth. Conversely, at later stages of 
tumor progression, Caveolin-1 has been shown to 
promote tumor cell migration, multi-drug resistance 
and, therefore its presence correlates with poor patient 
prognosis. Whether Caveolin-1 elicits one or the other 
response seems dependent on the tumor type and the 
cellular context [11, 19]. In this review, we will focus 
predominantly on discussing the ability of Caveolin-1 to 
modulate processes associated with cell death and 
survival. 
The Tumor Suppressor Hypothesis 
 Caveolin-1 was first described as a highly tyrosine 
phosphorylated substrate in Rous sarcoma virus-
transformed fibroblasts, suggesting a role for the 
protein in the transformation process [23-25]. Later on, 
Caveolin-1 mRNA and protein levels were shown to be 
down-regulated in oncogene-transformed fibroblasts in 
culture [26] and re-expression of Caveolin-1 was 
sufficient to revert the transformed phenotype as well 
as prevent anchorage-independent growth of these 
cells [27]. In addition, Caveolin-1 down-regulation using 
antisense oligonucleotides is sufficient to drive NIH3T3 
cell transformation [28]. Also, Caveolin-1 expression is 
reduced in several human tumors, including lung [29], 
mammary [30], colon [15, 31] and ovarian carcinomas 
[32], as well as sarcomas [32] and re-expression of 
Caveolin-1 often (but not always) results in reversal of 
characteristics associated with the transformed 
phenotype. Consistent with these results, lung 
hyperplasia and predisposition to mammary, as well as 
carcinogen-induced skin hyperplasia and tumor 
formation are observed in Caveolin-1 knock-out mice 
[4-5, 33-35]. These results indicate that Caveolin-1 
displays properties and characteristics of a tumor 
suppressor molecule in a variety of cellular settings. 
However, data to the contrary is also available (see 
subsequent section). 
 Initially, loss of Caveolin-1 in tumors was associated 
with the observation that the Caveolin-1 gene localizes 
to the D7S522 locus, a site frequently deleted in human 
cancers [36]. Generally, however, loss of Caveolin-1 
expression in tumors is now thought to occur via 
epigenetic mechanisms, including DNA methylation, 
rather than mutational changes. A detailed discussion 
of such mechanisms, as well as transcriptional 
pathways controlling Caveolin-1 expression can be 
found elsewhere [11]. However, a P132L mutation in 
Caveolin-1 was detected in 16% of human breast 
cancer patients analyzed in one study [37]. Rather 
intriguingly, this mutation results in a protein that acts 
as a dominant negative by promoting degradation of 
wild-type Caveolin-1 [38]. Additional mutations have 
been described in breast cancer since then [39]. Also, 
Caveolin-1 expression is regulated at the post-
transcriptional level in a differential manner by ROS 
species and subsequent proteasome-mediated 
degradation [40]. To what extent this might be a 
relevant mechanism in the tumor environment remains 
to be established. 
 In summary, a variety of mechanisms have been 
described that may contribute to loss of Caveolin-1 
without implicating the need for mutations. In 
conjunction, these posit Caveolin-1 as a non-
conventional tumor suppressor protein. 
Caveolin-1 in Multi-Drug Resistance and Metastasis 
 Caveolin-1 is reportedly also a protein that 
promotes more aggressive traits in tumor cells, such as 
metastasis and multidrug resistance. In normal prostate 
tissue Caveolin-1 is not expressed, but levels increase 
upon tumor formation in mouse models and human 
patients [41-44]. Moreover, Caveolin-1 favors metas-
tasis of prostate cancer cells via an autocrine/paracrine 
mechanism [45-46]. Likewise, Caveolin-1 expression is 
increased in multi-drug resistant MCF7 breast cancer 
cells [47] and promotes anchorage-independent 
survival by preventing anoikis [48-49]. In patients, 
Caveolin-1 presence is associated with elevated 
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metastasis, multi-drug resistance and poorer prognosis 
[50-52]. Interestingly, Caveolin-1 is associated with 
polarized distribution of cell signaling components and 
Caveolin-1 is required for cell polarization and 
migration in two and three dimensions [53-55]. 
Additionally, re-expression of Caveolin-1 in lung 
adenocarcinoma cells is sufficient to promote filopodia 
formation, cell migration and enhance the metastatic 
potential of these cells [56]. Furthermore, phosphory-
lation of Caveolin-1 on tyrosine favors cell migration 
and anchorage-independent growth via the adaptor 
protein Grb7 [57]. 
 These observations strongly favor the notion that 
Caveolin-1 displays traits that cannot be reconciled 
with its definition as a tumor suppressor. Indeed, 
Caveolin-1 is known to promote tumor formation and, in 
prostate cancer, its presence correlates with poor 
patient prognosis and survival. Indeed, Caveolin-1 
expression increases in primary tumors from prostate 
[44] and certain leukemia derived cell lines [58]. Also, 
in prostate cancer cells Caveolin-1 presence enhances 
tumor growth and favors metastasis [41-42, 46, 59]. 
Importantly, Caveolin-1 expression in tumor samples is 
not restricted to tissues, like the prostate, where 
Caveolin-1 levels are low under normal conditions. For 
example, increased expression is also observed in 
colon [31] and breast cancer [48, 52, 60], cancer cells 
where tumor development is associated with initial 
Caveolin-1 loss (see Fig. 1). 
 A possible explanation for these discrepancies is that 
Caveolin-1 functions as a tumor suppressor in systems 
where negative signaling events downstream of Caveolin-
1 prevail. Alternatively, Caveolin-1-mediated positive 
signaling is likely to be important in those cases where 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Dual role of Caveolin-1 in cancer. The ability of Caveolin-1 to participate in events that favor cell proliferation or 
apoptosis is reflected in the dual role the protein is proposed to play in cancer. In some tissues (breast, lung, colon), consistent 
with function as a tumor suppressor, Caveolin-1 expression is reduced (light gray dashed line) in the early stages of cell 
transformation and tumor development. However, as tumors progress, changes occur that generate a “permissive” cellular 
context. These may include alterations within the cell associated with epithelial-mesenchymal transition, such as the loss of E-
cadherin. Alternatively, changes in the tumor cell environment due to inflammation (see text) may also contribute to generating 
such a “permissive” context. Upon re-expression of Caveolin-1 (black dashed line), triggered by mechanisms that remain to be 
defined, the protein may develop radically different characteristics (note transition in cell morphology) and promote traits 
associated with enhanced malignancy (multidrug resistance and metastasis). In this context, phosphorylation of Caveolin-1 on 
Tyrosine-14 is likely to represent a process that promotes tumor cell migration and enhances metastasis. In other tissues, 
including prostate, Caveolin-1 is not normally expressed; however, as tumors progress, increased expression may be detected, 
which is then associated with enhanced tumor cell malignancy, as indicated in the above model. 
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presence of the protein is associated with more 
aggressive tumor behavior. For additional information in 
this respect, the interested reader may wish to consider 
previous reviews where such ideas have been discussed 
extensively [11, 61]. A corollary to this concept is that 
Caveolin-1 function as a tumor suppressor is linked to 
events favoring cell death, while more aggressive tumor 
behavior is likely to be associated with Caveolin-1-
dependent mechanisms that favor cell survival. The 
following discussion in this article will focus on these 
aspects of Caveolin-1 function. 
Caveolin-1-Mediated Control in Signaling 
 Caveolin-1 is viewed as a negative regulator in 
signaling, based on observations linking interaction 
with Caveolin-1 to subsequent inhibition of target 
protein function. Many of these interactions, such as 
those with the epidermal growth factor receptor, Src 
kinases, the Ras/Raf/MAPK pathway, PKCs and 
endothelial nitric oxide synthase (eNOS), occur via the 
scaffolding domain of Caveolin-1 (CSD; amino acids 
82-101) and the scaffolding domain binding domain 
(CBD) found in the respective target proteins [3]. 
However, as highlighted in Fig. (2), several other 
modes of action are apparent for Caveolin-1 and 
association with Caveolin-1 does not necessarily block 
target protein function. 
Other Mechanisms of Post-Transcriptional Control 
 Alternative modes of action include enhanced 
proteasome-mediated degradation of the inducible 
isoform of nitric oxide synthase (iNOS) via an 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Schematic showing some of the signaling pathways modulated by Caveolin-1. Caveolin-1 is depicted as a highly 
versatile molecule that regulates signaling processes both at the transcriptional and post-transcriptional level. To the left, 
Caveolin-1 is shown to participate in the formation of a multi-protein complex, which includes E-cadherin/-catenin and helps 
sequester -catenin to the membrane, thereby precluding -catenin/Tcf-Lef-dependent transcription of genes like Survivin, 
COX-2 and Cylcin D1. In the center, Caveolin-1 can be seen associating with many different molecules and modulating their 
function. Some of these interactions involve the CSD and are inhibitory. For others, association may or may not lead to inhibition 
(MDR modulation). Then again in the section, “Other Mechanisms”, interactions with Caveolin-1 may lead to degradation, as is 
the case for iNOS. Alternatively, phosphorylation of Caveolin-1 on Tyrosine-14 favors interactions and signaling associated with 
cellular “stress” responses. Finally, to the right some connections between Caveolin-1 and Fas (CD95) are depicted. For details 
on how these processes relate to the ability of Caveolin-1 to promote cell survival or death, see relevant sections in the text. 
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interaction that presumably requires the Caveolin-1 
segment 101-135 [62-63]. Phosphorylation of Caveolin-
1 on Tyr-14 by members of the Src-family kinases, and 
other tyrosine kinases including the insulin receptor 
[64-66] permits recruitment of the COOH-terminal Src 
kinase (Csk), which then phosphorylates Src on 
residue Y527 favoring intramolecular binding to the 
SH2 domain and auto-inhibition of the kinase [67-68]. 
Since this site is phosphorylated in response to a 
variety of growth factors (insulin, PDGF, EGF) and 
stress stimuli, including UV irradiation, mechanical and 
oxidative stress, as well as hyperosmolarity, 
phosphorylation of Caveolin-1 on Tyr-14 may constitute 
an important element in cellular stress responses [68-
69]. Indeed, although Caveolin-1 knock-out animals are 
viable and fertile, their ability to respond to specific 
stress situations, as well as life-span in general is 
diminished [4-5, 17-18]. Phosphorylation of Caveolin-1 
on Tyr-14 is also linked to augmented anchorage-
independent growth and cell migration via a Grb7-
dependent mechanism [57], as well as association with 
type-I matrix metalloproteinase [70]. Additionally, 
phosphorylation at this site is considered a crucial 
event in integrin-regulated membrane microdomain 
internalization [71-72], as well as EGF-induced 
caveolae formation [73]. Moreover, presence or 
absence of this site may account for functionally 
non-redundant roles ascribed to the two Caveolin-1 
isoforms 1 and 1 in early vertebrate development 
[74]. Thus, phosphorylation on Tyr-14 is clearly 
relevant to Caveolin-1 function in a number of settings; 
however, the responses associated with this event are 
highly variable. 
Mechanisms of Transcriptional Control 
 Caveolin-1 promotes cell cycle arrest via a 
p53/p21Waf1Cip1-dependent pathway [75]. Also 
Caveolin-1 enhances premature senescence in primary 
murine fibroblasts [76]. Oxidative stress-induced sene-
scence involves augmented Caveolin-1 expression via 
p38 MAPK activated Sp1-dependent transcription [77]. 
Caveolin-1 expression and intracellular distribution 
depend on cell-cell adhesion in a manner related to 
that observed for -catenin [78-79]. Indeed, studies 
have now implicated Caveolin-1 as a negative regulator 
of -catenin-Tcf/Lef-dependent transcription [28, 80-
81]. Although it remains unclear whether the interaction 
between Caveolin-1 and -catenin is direct or indirect, 
recruitment of -catenin to caveolae and/or Caveolin-1-
containing protein complexes at the cell surface is 
thought to preclude -catenin Tcf/Lef-dependent 
transcription of target genes [28, 81-82]. Specifically, 
Caveolin-1 is suggested to promote cell cycle arrest in 
G0/G1 and decrease the number of cells in S phase by 
decreasing Cyclin D1 expression [75, 83]. More 
recently, work from our group has shown that 
expression of the Inhibitor of Apoptosis (IAP) protein 
Survivin and also cyclooxygenase-2 (COX-2) are 
down-regulated by Caveolin-1 in a -catenin-Tcf/Lef-
dependent manner [81-82]. Interestingly, reduction of 
survivin expression has been associated with 
enhanced sensitivity to anti-cancer drugs [84].  
 
Moreover, reduction of Survivin expression provides an 
explanation for several alterations caused by the 
presence of Caveolin-1, including a decrease in the 
number of cells in G2M and an increment in the 
susceptibility to apoptosis [81]. Consistent with these 
observations, the absence of Caveolin-1 in vivo in 
knock-out mice leads to hyper-proliferation and 
enhanced -catenin-Tcf/Lef signaling in both intestinal 
crypts and mammary gland stem cells [85-86]. 
Caveolin-1-Dependent Mechanisms that Modulate 
Cell Proliferation and Survival 
 Caveolin-1 has long been implicated in cell death, 
either by sensitizing to or directly inducing apoptosis. A 
variety of possible mechanisms have been associated 
with such Caveolin-1 functions in cells. Initially, many 
were linked to the idea that Caveolin-1 binds to and 
inhibits crucial constituents of cell survival pathways, 
thereby favoring mitochondrial permeability and 
caspase activation. Some examples involving CSD-
CBD interactions, as well as others are summarized 
below with a focus on the pathways Ras/Raf/ERK, 
PI3K/Akt, and Wnt/-catenin and their role in cell death 
or survival. 
The Ras/Raf/ERK Connection 
 Strong links between Caveolin-1 and the 
MAPK/ERK pathway were established early on in 
oncogenically transformed fibroblasts, where Caveolin-
1 expression is lost or diminished [26] and upon 
re-expression of Caveolin-1 cell transformation is 
reversed. In Ras-transfromed fibroblasts, this 
correlates with substantially reduced MAPK/ERK 
signaling and augmented apoptotic cell death [27]. In 
NIH3T3 fibroblasts, down-regulation of Caveolin-1 
using specific siRNA is sufficient to hyperactivate the 
MAPK/ERK pathway and induce cell transformation 
[78]. Also, in Caveolin-1 knock-out mice, signaling via 
the MAPK/ERK pathway is increased and associated 
with increased sensitivity to topically applied 
carcinogens, cardiac hypertrophy and neointimal 
hyperplasia [33, 87-88]. Moreover, in human head and 
neck squamous cell cancer, Caveolin-1 inhibits the 
ERK pathway and cell growth [89], and in human 
laryngeal carcinoma cell lines, Caveolin-1 interaction 
with the EGFR is associated with reduced MAPK/ERK 
phosphorylation and increased apoptotic cell death 
[90]. 
 Alternatively, chronic airway diseases, including 
asthma, are associated with increased airway smooth 
muscle (ASM) mass, likely due to enhanced 
proliferation. In ASM cells, down-regulation of 
Caveolin-1 using siRNA leads to spontaneous 
MAPK/ERK activation and increased proliferation in the 
absence of mitogens. Moreover, PDGF stimulation 
reversed the ability of Caveolin-1 to inhibit MAPK/ERK 
signaling [91]. Taken together, Caveolin-1-mediated 
inhibition of the MAPK/ERK pathway appears to 
preclude inappropriate cell proliferation and also 
promote cell death. 
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The PI3K/Akt Connection 
 The Phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway is an important signaling pathway activated by 
growth factors that is involved in growth control and cell 
survival [92-95]. Interestingly, PI3K has been found in 
caveolae fractions in different cells, including 
fibroblasts, endothelial cells, and myeloid-derived cells 
[96] and, consistent with a role as a tumor suppressor, 
Caveolin-1 has been suggested to inhibit PI3K activity 
[97]. In a cellular context, this may also involve 
stabilizing the tumor suppressor phosphatase PTEN 
[98]. 
 Strangely, however, Caveolin-1 reportedly sensitizes 
L929 fibrosarcoma, HEK293 and Hela cells to TNF, 
staurosporine, H2O2 and arsenite [99-100] via PI3K/Akt 
activation, possibly via a ceramide-mediated 
mechanism [100]. The latter finding is unexpected 
since Caveolin-1 also has been shown to promote 
ceramide-dependent cell death via PI3K/Akt activation 
[101]. Moreover, upon inhibition of PI3K/Akt with 
inhibitors, like LY-294002 or wortmannin, survival of 
TNF--treated L929 cells is substantially improved. 
Similar effects are also seen in HEK293 and HeLa 
cells. Thus contrary to the general view, Caveolin-1 is 
required for TNF--induced cell death in L929 cells, 
and this effect is dependent on activation of a PI3K/Akt 
signaling pathway [99]. See data summarized in the 
Table 1. 
 These examples suggest that Caveolin-1-
dependent regulation of the PI3K/Akt pathway and also 
PTEN play a significant role in modulating cell survival, 
although the precise consequences of Caveolin-1 
interaction with this pathway appear to vary quite 
dramatically. 
The -Catenin/Tcf-Lef Connection 
 As mentioned, results from several laboratories 
including our own, implicate Caveolin-1 in the 
regulation of a significant number of -catenin/Tcf-Lef 
target genes, including Cyclin D1, Survivin and COX-2. 
In doing so, the presence of Caveolin-1 modulates 
parameters associated with cell proliferation and cell 
death. Interestingly, however, while Caveolin-1-
mediated suppression of Survivin was observed in a 
variety of different cell lines available in the laboratory 
[81], there were notable exceptions. Specifically, 
expression of Caveolin-1 in a sub-line derived from the 
human adenocarcinoma cell line HT29, termed 
HT29(US), that was obtained by selection for higher 
metastatic potential, did not alter Survivin expression or 
cell proliferation. Since loss of E-cadherin is often 
associated with metastasis, we asked whether the 
absence of E-cadherin might be linked to the inability of 
Caveolin-1 to regulate Survivin. Indeed, E-cadherin 
levels are reduced in HT29(US) cells, as compared to 
HT29 cells obtained from ATCC, referred to as 
HT29(ATCC) cells. Furthermore, re-expression of E-
cadherin is sufficient to restore the ability of Caveolin-1 
in HT29(US) cells to sequester -catenin to the plasma 
membrane, inhibit Survivin expression and control cell 
proliferation [82, 102]. Similar results were obtained in 
metastatic murine melanoma B16-F10 cells, where the 
simultaneous expression of Caveolin-1 with E-cadherin 
not only reduced significantly proliferation but also 
enhanced cell death [102]. Taken together, these 
results indicate that loss of E-cadherin, as is frequently 
observed during metastasis, provides a molecular 
understanding of how Caveolin-1 function can switch in 
a cell context-dependent fashion from functioning as a 
tumor suppressor to promoting characteristics 
associated with more malignant tumor cell behavior 
(see Fig. 1). 
 Enhanced expression of COX-2 is also frequently 
observed in human cancers and, as for Survivin, 
augmented presence is associated with increased 
tumor cell survival. Indeed, due to its known role in 
carcinogenesis, angiogenesis and apoptosis, COX-2 
has been proposed as a good target for the develop-
ment of chemopreventive and anti-cancer drugs [103]. 
Our studies also revealed that Caveolin-1 reduces 
COX-2 expression via a -catenin/Tcf-Lef-dependent 
transcriptional mechanism. Interestingly, accumulation 
of prostaglandin E2 (PGE2) in the medium of cancer 
cells is reduced by Caveolin-1 expression and exo-
genous addition of PGE2 to cells is sufficient to revert 
Caveolin-1-mediated effects. Thus, on the one hand 
Caveolin-1 presence interrupts a potent feed-forward 
amplification loop involving the COX-2-PGE2 axis and 
downstream activation of -catenin/Tcf-Lef-dependent 
transcription of genes, including COX-2 itself, as well 
as Survivin, which promote cell survival and proliferat-
ion. Alternatively, the observation that exogenous 
PGE2 reverts Caveolin-1 mediated suppression of 
-catenin/Tcf-Lef-dependent transcription, even in the 
presence of E-cadherin, indicates that Caveolin-
1-functions associated with its potential role as a tumor 
suppressor are “conditional” and depend on the cellular 
environment. In a pro-inflammatory context, where 
molecules like PGE2 are present, the ability of 
Caveolin-1 to function in this sense is limited. Finally, 
the results indicate that Caveolin-1-function in any 
given cell is not only determined by existing constraints 
within the same cell, but is also subject to modulation 
by ongoing processes in neighboring cells. 
Caveolin-1 and Apoptosis 
 As discussed in previous sections, Caveolin-1 
impacts on cell survival pathways in a number of ways 
that ultimately may predispose to or even directly 
promote cell death. In this section, we will focus on a 
few select examples where direct connections to either 
the extrinsic or intrinsic cell death pathways are 
apparent. 
 Binding of ligands to the appropriate death 
receptors, induces receptors aggregation and caspase-
8-, followed by caspase-3/7 activation, leading to cell 
death via the extrinsic pathway [104]. A potential 
Caveolin-1 binding motif (G53LHHDGQFCH) was 
identified in the human death receptor Fas sequence 
and, in a model of lung epithelial apoptosis induced by 
hyperoxia, Caveolin-1 and Fas colocalization as well as 
interaction were followed by Fas multimerization and 
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Death-Induced Signaling Complex (DISC) formation. In 
this context, Caveolin-1-dependent Fas receptor 
aggregation and the efficiency of BID cleavage 
required Fas palmitoylation. The absence of Caveolin-1 
in deficient cells (Cav-1/) disrupted DISC formation. 
Moreover, mutation of Tyrosine-14 (Y14F) disrupted 
hyperoxia-induced interaction between BID and 
Caveolin-1, decreased tBID formation and increased 
resistance to hyperoxia-induced apoptosis [105]. 
 Recently, Autophagic microtubule-associated 
protein 1 light chain 3B (LC3B) has been studied as a 
regulator of lung cell death. In epithelial cells, LC3B 
forms a complex with the death receptor Fas in lipid 
rafts, which requires the presence of Caveolin-1. The 
different complexes, Fas-LC3B, Fas-Caveolin-1 and 
the Caveolin-1-LC3B were observed in epithelial cells 
under basal conditions; however, these complexes 
dissociated rapidly after cellular treatment with 
cigarette smoke. LC3B knockdown reduces DISC 
Table 1. Caveolin-1 Expression Favors Cell Death and Decreases Proliferation 
 
Model Manipulation Effects Implicated Signaling Pathway Ref. 
OVCAR-3 
ovarian carcinoma cells 
Expression of Caveolin-1 
Reduced tumor cell survival 
in vitro 
- [32] 
NIH3T3 cells 
Expression of P132L 
Caveolin-1 (mutation 
observed in some human 
breast cancers) 
Increased proliferation ERK/p38 [37] 
T24 bladder carcinoma and 
NIH3T3 cells 
Expression of Caveolin-1 
Increased sensitivity to 
apoptosis 
PI3K/Akt [149] 
v-Abl-transformed and H-Ras 
(G12V)-transformed NIH 3T3 
cells 
Re-expression of Caveolin-1 
Reduced anchorage-
independent growth 
Ras/ERK [27] 
Caveolin-1 knock-out mouse Carcinogen treatment 
More rapid tumor 
development 
Ras/ERK/CyclinD1 [33] 
NIH3T3 and MEF cells Caveolin-1 expression 
G0G1 cell cycle arrest, 
reduced proliferation 
p53/p21
WAF1/Cip1
 [75] 
MEF cells Caveolin-1 expression Induction of senescence - [76] 
MCF-7, human breast cancer 
cells 
Caveolin-1 reexpression Induction of senescence - [77] 
Mouse peritoneal 
macrophages 
Simvastatine induced 
apoptosis 
Increase in Caveolin-1 
expression 
- [112] 
Human airway smooth muscle 
cells 
Disruption of caveolae and 
siRNA-knockdown of 
Caveolin-1 
Decreased proliferation p42, p44 ERK [91] 
HEp2 laryngeal squamous cell 
cancer cells 
stable over-expression of 
Caveolin-1 
Increased apoptosis EGFR/ERK [90] 
T24 bladder carcinoma cells 
and NIH3T3 cells 
Caveolin-1 down-regulation 
with anti-sense RNA 
resistance to staurosporine-
induced apoptosis 
PI3K/Akt [149] 
A431 human epidermoid 
carcinoma cells, DU145 
prostate cancer cells, A549 
human non-small cell lung 
cancer cells. 
Caveolin-1 down-regulation 
Increased tumor cell 
invasion 
Increased -catenin dependent 
transcriptional activity 
[80] 
HT29, DLD-1 human colon 
cancer and HEK293T human 
embryonic kidney cells 
Augmented Caveolin-1 
expression 
Reduced cell proliferation 
-catenin-Tcf/Lef, COX-2 and 
PGE2 
[82] 
HT29US human colon cancer 
cells and B16F10 mouse 
metastatic melanoma cell line 
(both lacking E-cadherin) 
Caveolin-1 and E-cadherin 
expression 
Reduced proliferation and 
increased apoptosis 
-catenin-Tcf/Lef and Survivin [102] 
HEK293T and ZR75 breast 
cancer cells 
Ectopic expression of 
Caveolin-1 
Increased apoptosis -catenin-Tcf/Lef and Survivin [81] 
NIH3T3 cells 
siRNA-mediated silencing of 
Caveolin-1 
Enhanced proliferation -catenin-Tcf/Lef and Survivin [81] 
The table summarizes available evidence linking Caveolin-1 presence to reduced proliferation and/or increased cell death. The cell type studied, the experimental 
approach used to manipulate Caveolin-1 levels, the effects observed, the signaling pathways involved and the corresponding references are indicated (see text for 
details). 
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formation, in epithelial cells. Therefore, in this model, 
Fas is sequestered by Caveolin-1 and thus regulates 
the extrinsic apoptosis pathway. Additionally, LC3B is 
proposed also to sequester Fas in the basal state. 
Hence, the net effect of LC3B expression is pro-
apoptotic during cigarette smoke exposure [106-107]. 
 Caveolin-1 is also implicated in regulating the 
intrinsic apoptosis pathway via studies that establish a 
connection with acetylcholinesterase (AChE). 
Previously, AChE activity was found to increase in 
various types of apoptotic cells [108] and 
pharmacological inhibition of AChE, as well as anti-
sense RNA-mediated down-regulation of AChE 
prevented apoptosis. At the onset of apoptosis, AChE 
was found in the cytoplasm and then, upon 
commitment to cell death, the enzyme accumulated in 
the nucleus and in apoptotic bodies [108-109]. 
Moreover, AChE interacts with Caveolin-1 during 
apoptosis in events that precede apoptosome 
formation. While AChE plays a crucial role in promoting 
oligomerization of Apaf-1, Caveolin-1 appears neither 
to interact with cytochrome C nor with Apaf-1 [110]. 
 Apoptosis of macrophages is considered important 
for determining the efficiency of immune responses. 
Treatment of isolated macrophages activated in vivo in 
mice with apoptosis-inducing agents lead to a dramatic 
increase in Caveolin-1 levels while Caveolin-2 is not 
affected. Phosphatidylserine (PS) externalization is 
considered a defining feature associated with apoptosis 
[111]. Interestingly, Caveolin-1 is present in lipid rafts 
and colocalizes with PS at the cell surface of apoptotic 
macrophages, where it is suggested to be involved in 
the efficient externalization of PS [112]. Taken 
together, these observations link Caveolin-1 directly to 
the regulation of mechanisms that are relevant to the 
execution of both the extrinsic and intrinsic apoptosis 
pathways. 
Caveolin-1 – Mediated Survival Mechanisms 
 As mentioned, Caveolin-1 was initially implicated as 
an “oncosupressor” that blocks pathways relevant to 
cell transformation. Meanwhile, however, it has 
become clear that Caveolin-1 may also promote 
signaling events that favor cell survival [113-114]. In 
this section, we will focus on discussing such events. 
 The down-regulation of Caveolin-1 in H9C2 rat 
cardiomyoblasts with Cav-1-siRNA reduces 
significantly Insulin-like Growth Factor-I Receptor (IGF-
IR) tyrosine phosphorylation and Akt activation after 
IGF-I stimulation and, in these cells, IGF-I was unable 
to prevent serum withdrawal-induced apoptosis [115]. 
In endothelial HUVECs, Caveolin-1 down-regulation 
inhibits IGF-I and insulin-induced activation of eNOS 
(endothelial nitric oxide synthase), an anti-apoptotic 
factor in these cells [116]. Moreover, Caveolin-1 seems 
to play a pro-survival role in prostate cancer cells by 
promoting PI3K/Akt signaling. Caveolin-1 binds to and 
inhibits the serine/threonine protein phosphatases PP1 
and PP2A, leading to higher PDKI, Akt and ERK1/2 
activities and a decrease in thapsigargin-induced 
apoptosis in the human prostate cancer cell line 
LNCaP [117]. Also, the over-expression of Caveolin-1 
protects against c-myc-stimulated apoptosis in LNCaP 
cells [118] and loss of Caveolin-1 favors apoptosis of 
prostate tumor cells in a transgenic adenocarcinoma 
mouse prostate (TRAMP) model [119]. Moreover, 
physical interaction between Caveolin-1 and the 
putative oncogene Inhibitor of differentiation/DNA 
binding (ID-1) plays an essential role in the epithelial-
mesenchymal transition, cell migration and resistance 
to taxol-induced apoptosis in the human prostate 
cancer cell lines LNCaP and 22RV1. Again, the 
observed anti-apoptotic effects depend on the PI3K/Akt 
pathway [120]. 
 Anti-apoptotic functions of Caveolin-1 also have 
been reported in others cell types. In primary cortical 
neurons from neonatal rats, the expression of 
Caveolin-1 protects from ischemic cell death induced 
via stimulation of the N-methyl-D-aspartate receptor 
(NMDAR). In these cells, Caveolin-1 is thought to favor 
the correct localization of the NMDAR/Src tyrosine 
kinase family/ERK signaling components [121]. In 
lymphoblastoid TK6 cells, expression of Caveolin-1 
protected against UV irradiation-induced apoptosis, as 
well as promoted proliferation after this insult [122] and 
knock-down of Caveolin-1 with siRNA sensitized 
human ductal adenocarcinoma cells to ionizing 
radiation [123]. Besides, NO-induced resistance to 
anoikis mediated by Caveolin-1 in human lung 
carcinoma NCI-H4060 cells and over-expression of 
Caveolin-1 protects against detachment-induced 
apoptosis [124]. Over-expression of Caveolin-1 in 
HepG2, a hepatocellular carcinoma cell line, protects 
from serum deprivation-induced apoptosis, and also 
enhances migration and invasion by up-regulating 
MMP-2, MMP-9 and VEGF expression, suggesting that 
Caveolin-1 could be a critical pro-survival factor in 
hepatocellular cancer [125]. High glucose levels induce 
apoptosis in HLE-B3, a lens epithelial cell line, and this 
effect is observed concomitant with a decrease in 
Caveolin-1 expression. Upon simvastatin (3-hydroxy-3-
methylglutaryl coenzyme A inhibitor) or EGF addition to 
HLE-B3 cells cultured to high glucose-medium, 
expression of Caveolin-1 increases while apoptosis 
decreases [126]. Interestingly, Caveolin-1 has been 
found to prevent oxidative damage in human SK-N-MC 
neuroblastoma cells. The populations of DAF-2DA-
positive (NO producers) and Annexin V-positive cells 
were remarkably reduced by cell treatment with the 
CSD (Caveolin-1 scaffolding domain) peptide and 
Caveolin-1 transfection, but not by CSC, scrambled 
control peptide, or transfection with an empty vector. 
Indeed, in this study hypoxia activated iNOS and 
promoted NO production, resulting in an up-regulation 
of Caveolin-1 expression. This increase protected 
neuroblastoma cells against oxidative injury by 
inhibiting iNOS expression and NO production. The 
results suggest that up-regulation of Caveolin-1 in 
response to hypoxia may serve to prevent oxidative 
injury in neuroblastoma cells [127]. 
 Here it is important to note that Caveolin-1 not only 
protects from apoptosis by enhancing anti-apoptotic 
signaling in cell lines, but reportedly also plays a similar 
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role in normal cell physiology. Indeed, the absence of 
Caveolin-1 in knock-out mice induces cell damage and 
apoptosis in thyrocytes. In this case, the absence of 
Caveolin-1 leads to thyrocyte dysfunction, excessive 
oxidative stress and then finally cell death [128]. Also, 
genetic ablation of Caveolin-1 in mice increases the 
volume of cerebral ischemia due to impaired 
angiogenesis of vascular endothelial cells, whereby the 
expression of Caveolin-1 appears to be necessary to 
increase the protein levels of eNOS after an ischemic 
insult [129]. 
 In summary, these reports suggest that besides its 
well documented pro-apoptotic role, Caveolin-1 also 
acts as an anti-apoptotic and pro-survival factor in 
various cell types, whereby several possible 
mechanisms appear to be involved. Thus, as already 
mentioned, Caveolin-1 plays a highly ambiguous role in 
the regulation of cell survival and proliferation 
pathways, whereby the observed outcomes appear to 
depend largely on the cell context. 
Caveolin-1 and Drug-Resistance 
 Chemotherapy is one of the most frequently used 
treatments against cancer. Unfortunately, cancer cells 
often adapt to this challenge by becoming resistant, 
thereby avoiding drug-induced cell death [130]. Several 
reports suggest that Caveolin-1 participates as an 
important mediator of drug-resistance in cancer cells. 
In patients, up-regulation of Caveolin-1 levels is 
frequently observed in advanced stages of lung [51, 
131], prostate [42, 44], breast [44], pancreas [132] and 
renal cancer [133]. In these cases, Caveolin-1 is 
associated with poor patient prognosis and reduced 
patient survival. Moreover, in lung cancer patients, 
Caveolin-1 expression is inversely correlated with 
responses to gemcitabine, since absence of Caveolin-1 
expression is associated with increased 
responsiveness to therapy and patient survival. These 
observations provide strong evidence favoring the 
notion that Caveolin-1 presence is associated with the 
development of drug-resistance [51]. 
 These clinical data are complemented by findings in 
cell lines that correlate enhanced Caveolin-1 with the 
development of drug resistance. In colon cancer cells, 
selection for methotrexate resistance is associated with 
increased Caveolin-1 expression [31, 134]. 
Interestingly, in HT29 cells siRNA-mediated Caveolin-1 
down-regulation reduces cell viability after 
metothrexate exposure [134]. Similar increases in 
Caveolin-1 levels are observed in colchicine-resistant 
HT29 colon cancer and adriamycin-resistant MCF7 
breast cancer cells. In these cell lines, Caveolin-1 
expression increased together with Caveolin-2 and 
glucosylceramide cell content. These changes were 
independent of P-glycoprotein expression, indicating 
that the observed changes in Caveolin-1 are not the 
consequence of P-glycoprotein induction [47]. 
Furthermore, in lung cancer cells augmented Caveolin-
1 expression is detected after chronic etoposide 
exposure [135] and acute bleomycin treatment [136]. In 
both cases, augmented Caveolin-1 expression 
correlated with cell survival [135-136]. In addition, 
augmented Caveolin-1 expression is observed in taxol 
and epothilone-resistant A549 cancer cells [43]. In this 
case, Caveolin-1 upregulation occurred in the absence 
of changes in P-glycoprotein [43]. Furthermore, in 
Ewing´s sarcoma cells incubated with doxorubicin an 
increase in Caveolin-1 levels is detected. In this case 
augmented Caveolin-1 expression is related to reduced 
doxorubicin-induced cell death [137]. In metastatic 
prostate cancer cells, unlike other cancers, higher 
Caveolin-1 protein levels are frequently observed. In 
this case, Caveolin-1 has been proposed as a 
metastasis gene, which participates in androgen 
resistance [59, 138]. As mentioned, in prostate cancer 
cells, Caveolin-1 mediated inhibition of apoptosis is 
associated with the transcription factor Id-1 (for inhibitor 
of differentiation and DNA binding). Caveolin-1 
interaction with Id-1 increased Bcl-2 and prevented 
taxol-mediated induction of apoptosis by decreasing 
caspase-3 and PARP cleavage [120]. Taken together, 
these data strongly suggest that increased Caveolin-1 
levels in cancer cell lines favors the development of the 
multidrug-resistant phenotype in a manner apparently 
unrelated to the presence of P-glycoprotein. 
 Given the significance of augmented Caveolin-1 
expression in advanced stages of cancer and the 
association there with multidrug resistance, it is 
tempting to speculate that Caveolin-1 presence favors 
mechanisms which help avoiding cell death. Indeed, in 
a mouse model of metastatic prostate cancer, anti-
sense mediated Caveolin-1 knock-down, enhanced 
sensitivity to androgen withdrawal. Interestingly, anti-
sense mediated decreases in Caveolin-1 levels also 
reduced prostate tumor volume and increased cell 
death and this effect was lost when mice were injected 
with testosterone. In vitro, in prostate cancer cells, 
Caveolin-1 specific anti-sense constructs induce cell 
death after testosterone removal. This effect was 
abrogated, when the cells were treated with the general 
caspase inhibitor Z-VAD-FMK [139]. Additionally, in 
human prostate cancer cells, Caveolin-1 presence 
favors phenylephrine-induced resistance to 
thapsigargin mediated cell death. This Caveolin-1-
dependent effect is characterized by reduced caspase-
3 activation and PARP cleavage in a Bax dependent 
fashion [140]. In addition, in renal cancer cells, 
Caveolin-1 is up-regulated after chronic treatment with 
doxorubicin. siRNA treatment against Caveolin-1 
reduces cell survival and activates the proapoptotic 
proteins PARP and Bax and reduces anti-apoptotic Bcl-
2 after doxorubicin treatment. These results point 
towards an anti-apoptotic role for Caveolin-1 in these 
cells. Also, pulmonary metastasis was reduced in 
SCID-mice injected with Caveolin-1 siRNA-transfected 
cells treated with doxorubicin, suggesting again that 
Caveolin-1 reduces sensitivity to chemotherapeutic 
agents both in vitro and in vivo [141]. Finally, Caveolin-
1 knock-down in MDCK cells over-expressing the drug 
transporter protein BCRP (for breast cancer resistance 
protein) sensitizes the cells to the chemotherapeutic 
agent mitoxantrone, thus reducing cell proliferation 
[142]. Altogether, these results indicate that Caveolin-1 
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participates significantly in facilitating the development 
of multidrug resistance. Thus, drugs that eliminate or 
reduce Caveolin-1 levels are expected to sensitize cells 
to drug-induced death. 
Mechanisms of Caveolin-1-Mediated Drug Resistance 
 The main transporters involved in the development 
of drug-resistance, predominantly as a consequence of 
over-expression, are P-glycoprotein and BCRP. Both 
belong to the ABC transmembrane transporter family 
that, in an energy-dependent fashion, transport drugs 
to the cell exterior, thereby reducing the effective 
intracellular concentration. Some anticancer-drugs that 
are known substrates for P-glycoprotein and BCRP 
include anthracyclines, topoisomerase inhibitors, 
taxanes and mitoxantrone among others [130]. 
Interestingly, a tight association has been noted 
between Caveolin-1 and P-glycoprotein. Indeed, both 
proteins co-distribute in the same detergent-resistant 
membrane fractions [47, 135, 143], and co-
immunoprecipitate in brain capillaries, rat brain 
endothelial, chinese hamster ovary and breast cancer 
cells [143-145]. This interaction appears to be 
mediated by the presence of a Caveolin-1-binding motif 
in P-glycoprotein [143]. In addition, both Caveolin-1 
and the MDR gene are co-expressed in normal and 
leukemia cells obtained from human patients [146]. 
However, despite these findings some groups have 
obtained evidence showing that Caveolin-1 represses 
P-glycoprotein function in brain-derived endothelial 
cells and breast cancer cells [145, 147]. Therefore, the 
role of Caveolin-1 interactions with P-glycoprotein and 
their consequences for P-glycoprotein activity remain 
controversial. However, as suggested in the previous 
sections, the ability of Caveolin-1 to promote drug-
resistance does not appear to be linked to 
P-glycoprotein expression. 
 Additionally, Caveolin-1 function in this context has 
been linked to another ABC transporter, the BCRP 
protein, since it was shown that Caveolin-1 co-distributes 
with BCRP in detergent-resistant membrane fractions and 
interacts there with BCRP [142, 148]. Interestingly, in 
Caveolin-1 knock-down cells, BCRP activity was reduced 
and the cells became more sensitive to 
mitoxantrone-induced reduction in cell proliferation [142]. 
These results clearly suggest that Caveolin-1 presence 
promotes BCRP function, although, at the molecular level, 
it remains unclear how this occurs. 
 Recently, an alternative mechanism was put 
forward to explain how Caveolin-1 presence may 
facilitate multi-drug resistance and protect against cell 
death. In sarcoma cells, Caveolin-1 expression is 
associated with protection against doxorubicin-induced 
cell death. Indeed, re-expression of Caveolin-1 in cells 
in which Caveolin-1 had previously been silenced lead 
to a reduction in apoptosis after doxorubicin treatment. 
Importantly, loss of Caveolin-1 correlated with a 
reduction in the active, phosphorylated form of protein 
kinase C (PKC). Interestingly, drug-sensitization 
after Caveolin-1 knock-down was abrogated when 
PKC was overexpressed, suggesting that PKC may 
act downstream of Caveolin-1 to protect against cell 
death in drug-resistant cells [137]. Whether PKC acts 
in a similar fashion as a downstream effector of 
Caveolin-1 in other cellular systems remains to be 
shown. See data summarized in the Table 2. 
 Taken together, the data discussed strongly 
suggest that up-regulation of Caveolin-1 is observed in 
late stages of cancer and in drug-resistant cancer cell 
lines. Moreover, increased Caveolin-1 expression 
appears to favor cancer cell survival by preventing 
apoptotic cell death after exposure to chemothera-
peutics agents. Additionally, there is substantial 
evidence linking Caveolin-1 function to the ABC 
transporters, P-glycoprotein and BCRP, although the 
data remain controversial in this respect. Additional 
experiments are required to clarify this point. Finally, 
PKC has emerged as a potential effector molecule 
that mediates Caveolin-1-dependent protection against 
cell death in drug-resistant cells. Again, additional 
experiments are required to confirm the relevance of 
these observations in other experimental models. 
The Two Sides to Caveolin-1: Summary and 
Outlook 
 The literature revisited in this review highlights 
Caveolin-1 as a protein, which plays a highly ambiguous 
role in cancer. As depicted in the Fig. (1), Caveolin-1 
expression is frequently reduced or suppressed in early 
stages of cancer, by mechanisms that are not entirely 
clear, although methylation of CpG-rich islands in the 
promoter region has been suggested. As might be 
expected for a tumor suppressor, re-expression of the 
protein frequently reduces tumor growth in vivo observed 
for a number of different tumor cell lines. Despite such 
evidence, Caveolin-1 is also implicated in tumor 
progression, the development of multi-drug resistance 
and metastasis. Moreover, presence of the protein in 
tumors has been associated with poorer patient 
prognosis. Consistent with such ambiguity in function, this 
review summarized a considerable amount of data 
showing that Caveolin-1 can both favor cell proliferation 
and survival, as well as enhance processes that lead to 
cell death. While such distinct results may be attributed to 
use of different experimental systems, some reports 
suggest that this “switch” in function can occur within the 
same cell. To resolve this apparent dichotomy, our model 
proposes that both intracellular and extracellular changes 
help create a permissive environment. Loss of E-cadherin 
is highlighted as one possibility, but others include 
exposure to a pro-inflammatory environment, as was 
discussed. Hence, when Caveolin-1 is re-expressed, by 
again poorly defined mechanisms, restraints initially 
present in the non-transformed cells, no longer exist such 
that the protein now favors activities associated with more 
malignant tumor cell behavior. One possibility depicted 
here is phosphorylation on Tyrosine-14, a modification 
that is implicated in promoting cell migration and 
metastasis. To what extent this may contribute to other 
characteristics, such as multi-drug resistance remains to 
be defined. Thus, studies related to Caveolin-1 (and a few 
other select molecules not discussed here) are beginning 
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to alter the classic view suggesting that cancer originates 
as the consequence of mutations in either oncogenes or  
tumor suppressors. In doing so, they are likely also to 
alter how we go about treating the disease. As a corollary, 
a better understanding of Caveolin-1 biology and how 
function of the molecule changes throughout tumor 
development can be expected to help in the development  
of therapeutic strategies that harness its ability to promote 
cell death in tumor cells without undesired side effects. 
ABBREVIATIONS 
APC = Adenomatous polyposis coli 
COX-2 = Cyclooxygenase-2 
GSK-3 = Glycogen synthase kinase 3 
CSD = Caveolin scaffolding domain 
CBD = Caveolin binding domain 
Table 2. Caveolin-1 Expression Favors Cell Survival and/or Proliferation 
 
Model Manipulation Effects Implicated Signaling Pathway Ref. 
H9C2 
(rat hearth muscle) 
Down-regulation of 
Caveolin-1 with siRNA 
Inhibition of protection against serum 
withdrawal-induced apoptosis by IGF 
IGFR/Akt [115] 
HUVEC 
(human endothelium) 
Down-regulation of 
Caveolin-1 with siRNA 
Inhibition of IGF and Insulin-induced 
activation of eNOS as a pro-survival 
factor 
IGFR and IR [116] 
Over-expression of 
Caveolin-1 
Inhibition of thapsigargin-induced 
apoptosis 
PI3K/Akt/Erk 1/2 [117] 
Over-expression of 
Caveolin-1 
Inhibition of c-myc-induced apoptosis c-myc-induced apoptosis [118] 
LNCaP 
(human prostate) 
Over-expression 
Caveolin-1 
Resistance to taxol-induced cell death ID-1/PI3K/Akt [120] 
Cross between Cav1  
null mouse and TRAMP  
(transgenic adenocarcinoma  
of mouse prostate) mouse 
Generation of 
Cav1 (-/-) prostate tumors 
Inhibition of tumor progression Par4 and PTEN [119] 
Primary cortical neurons 
(neonatal rat neocortex) 
Down-regulation or  
knock-out of Caveolin-1 
Enhanced ischemic cell death 
N-methyl 
D-aspartate receptor/Src/ERK 
[121] 
TK6 cells 
(human spleen) 
Over-expression of 
Caveolin-1 
Enhanced proliferation after UV 
irradiation 
- [122] 
PATU8902, MiaPaCa2, 
Panc1 (human pancreatic 
carcinoma) 
Knock-down of 
Caveolin-1 
Sensitization to ionizing radiation -1-integrin/FAK [123] 
NCI-H4060 (human lung 
carcinoma) 
Over-expression of 
Caveolin-1 
NO-induced resistance to anoikis PI3K/Akt [124] 
HepG2 
(human hepatocellular 
carcinoma) 
Over-expression of 
Caveolin-1 
Inhibition of serum  
withdrawal-induced apoptosis 
Survivin [125] 
HLE-B3 
(human lens) 
Decreased Caveolin-1 
expression 
Increased high glucose-induced 
apoptosis 
- [150] 
SK-N-MC (human 
neuroblastoma) 
Up-regulation of  
Caveolin-1 
Protection against oxidative damage 
in hypoxia 
iNOS [127] 
Thyrocytes (mouse thyroid 
gland) 
Knock-out mouse 
Caveolin-1 
Cell damage and apoptosis in 
thyrocytes 
ROS production [128] 
Vascular endothelial 
cells (from mouse brain) 
Knock-out mouse 
Caveolin-1 
Enhanced cerebral ischemia by 
impaired angiogenesis 
eNOS [129] 
The table summarizes available evidence linking the presence of Caveolin-1 to cell survival and/or proliferation. The cell type or animal models studied, experimental 
approach used to manipulate Caveolin-1 levels, the signaling pathway involved and the corresponding references are indicated. Information concerning the signaling 
pathways involve was not always available (see the text for details). 
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IAP = Inhibitor of Apoptosis 
eNOS = Endothelial oxide nitric synthase 
iNOS = Inducible oxide nitric synthase 
MAPK = Mitogen activated protein kinase 
PGE2 = Prostaglandin E2 
TNF = Tumor necrosis factor alpha 
ASM = Airway smooth muscle 
PI3K = Phosphatidylinositol 3-kinase 
PTEN = Phosphatase and tensin homolog 
Tcf/Lef = Binding element 
DISC = Death-induced signaling complex 
LC3B = Protein 1 light chain 3B 
AChE = Acetylcholinesterase 
PS = Phosphatidylserine 
IGF-IR = Insulin-like growth factor-I receptor 
PP1 and = Serine/threonine protein phosphatases  
PP2   1 and 2, respectively 
TRAMP = Transgenic adenocarcinoma mouse  
   prostate model 
NMDAR = N-methyl-D-aspartate receptor 
MMP-2 and = Metalloproteinase 2 and 9, respectively 
MMP-9 
Z-VAD-FMK = Z-Val-Ala-Asp-fluoromethylketone 
PARPs = Poly ADP-ribose polymerases 
MDR = Multidrug resistance 
BCRP = ATP-binding cassette transporters 
PKC = Protein kinase C 
VEGF = Vascular endothelial growth factor 
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